Navidea Biopharmaceuticals, Inc. (NYSE MKT:  NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek® (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.

Rep. Patrick Meehan (R-Pa.) — a proponent of ending the medical device tax — was on hand to help open Siemens' second U.S. ultrasound factory, which is located in his district.

While verbal memory decline associated with Alzheimer’s disease has been well documented, a similarly relevant area of research has gone relatively uncharted until now. Those affected by the neurodegenerative disease also suffer loss of nonverbal memory function and researchers are mapping the effects of Alzheimer’s disease on brain regions dedicated to this area of cognition and finding newly blazed trails of neural activity, according to a study published April 26 in Neurology.

For patients with non-small cell lung carcinoma, volumetric data derived from quantitative PET imaging could provide more precision staging and inform physicians about patient survival, according to a study published in the March issue of the American Journal of Roentgenology.

A PET imaging technique gleaning information about both dopamine terminal integrity and amyloid burden in the brain may help researchers classify forms of mild cognitive impairment (MCI) and predict dementia risk, according to a study published online April 9 in The Journal of Nuclear Medicine.

An increasing number of studies are exploring the possibilities of cognitive reserve in Alzheimer’s patients with higher education levels. Specific neural networks have been found in an area of the prefrontal cortex that light up in educated subjects and compensate for neural damage in the beginning stages of the disease, according to research published in the June issue of The Journal of Nuclear Medicine.

A comparison between glucose mimicking F-18 FDG and F-18 FLT, which tracks cell proliferation, pegged F-18 FDG PET/CT as a better imaging technique for the diagnosis of differentiated thyroid metastases, according to a study published in the April issue of Radiology. 

(Knoxville, TN, UNITED STATES) April 11, 2013– ABT Molecular Imaging, Inc., in Knoxville, TN, has successfully achieved the installation and clinical use of its next-generation Biomarker Generator by the Sveta Marina University Hospital in Bulgaria. ABT’s next-generation product integrates a compact accelerator and micro-chemistry with integrated quality control, for single-dose biomarker production.